Muhammad Wasif Saif, Kathryn Huber, Martin D Goodman, Sarah McPartland
There remains great variability in the treatment for patients with borderline resectable pancreatic head cancers. Whethersurgery should be attempted or neoadjuvant therapy consisting of chemoradiation or chemotherapy alone is at some debate. Each neoadjuvant regimen does show efficacy but there is no clear consensus which would be most beneficial. We will discuss three abstracts (#4043, #4057, #e15082) that were presented in the 2013 ASCO Annual Meeting that will discuss neoadjuvant therapies and how they are related to getting an R0 resection.
